Nevertheless, more studies (e.g., prospective cohort designs) are needed to ascertain whether these two parameters could be utilized as predictive biomarkers for atherothrombotic stroke, as well as their sensitivity and specificity, since there are other diseases, such as oncological malignancies, which also present elevated CD137 levels, thus indicating that these markers could be nonspecific for stroke outcome measures. The gene discussed is TNFRSF9; the disease is stroke disorder.